伊克力西斯:Cabometyx在非功能性神经内分泌肿瘤中降低进展或死亡风险74%,在功能性肿瘤中降低60%

美股速递
May 30

伊克力西斯(Exelixis)宣布,其药物卡博替尼(Cabometyx)在治疗神经内分泌肿瘤方面取得了积极成果。数据显示,该药物在非功能性神经内分泌肿瘤患者中,将疾病进展或死亡的风险显著降低了74%。同时,在功能性神经内分泌肿瘤患者群体中,这一风险降低幅度也达到了60%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10